An item from the New York Times gives
me the chance to write about two great interests in the same blog piece:
bacteria (once a microbiologist, always a microbiologist) and cancer.
Fusobacterium nucleatum, an accomplice of colorectal cancer |
That bacterial infection might
cause or promote cancer was debated for most of the 20th century, but
with little solid evidence emerging to support the notions. During the 1980s, Barry
Marshall and Robin Warren (the former famously swigging down a flask of culture
broth to prove his hypothesis) established that Helicobacter pylori, a common corkscrew-shaped found in the
stomach, was an undisputable cause of gastric inflammation and ulcers.
Epidemiological studies involving
British, American and Japanese subjects confirmed that H.pylori carriage was indeed associated with an almost four-fold
increase in the likelihood of developing gastric cancer and resulted in the WHO
designating H.pylori as a Class I carcinogen.
Continuing research has established
that the relationship between H.pylori and cancer is not a simple one
of cause and effect, with H.pylori infection being a factor in
some, but not all, forms of stomach cancer and that H.pylori strains expressing
a particular cytotoxin, “CagA”, are more
strongly associated with an elevated risk of cancer than are non-producing
strains. Perversely, H.pylori
infection appears to be associated with a lower risk of oesophageal cancer.
A more recently uncovered “smoking
gun” is the presence of Fusobacterium
nucleatum, a common mouth-dweller, found in higher numbers in around half
of colorectal tumours than in the surrounding tissue. F.nucleatum- induced inflammation is cited as a plausible contributor
to CRC initiation and progression.
But, as with the Helicobacter story, there is no
clear-cut cause and effect between infection and cancer. Bacterial species are
rarely solitary and the inhabitants of the local milieu or “microbiome” may be
more important with respect to cancer initiation and/or progression than the
presence of F.nucleatum alone.
CRC may spread to other organs
and give rise to tumours in the liver. According to a recent Science
publication, if F.nucleatum and its
microbiome buddies are present in the original tumour, then they can accompany
the metastasizing cancer and pitch up in the liver. CRC dwelling F.nucleatum remained associated with tumours
even after their transplantation into mice. Moreover, dosing of tumour-bearing
mice with an F.nucleatum-killing
antibiotic slowed tumour growth.
Does this make a case for
antibiotic therapy or vaccine development to reduce CRC rates? Well, not yet.
Antibiotics therapy tends to ablate both the good and bad and, as is hinted at
in immuno-oncology studies, certain gut bacteria might positively influence
anti-cancer immune responses. And not all F.nucleatum
strains might be bad guys. However, it’s feasible that getting a better handle
on the mechanism(s) involved in the bacterial promotion of cancer might
identify new interventions to improve outcomes or recurrence rates.
Photo credit: CDC Public Image Library
Photo credit: CDC Public Image Library
Why is this bacterium hiding in
human tumors? Gina Kolata. New York Time online 23rd November 2017. http://tinyurl.com/ycztnrm4.
Analysis of Fusobacterium
persistence and antibiotic response in colorectal cancer. Bullman, S et al. Science 23rd November 2017:eaal5240 DOI:
10.1126/science.aal5240.
No comments:
Post a Comment